177 related articles for article (PubMed ID: 30824387)
41. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.
Gomila A; Shaw E; Carratalà J; Leibovici L; Tebé C; Wiegand I; Vallejo-Torres L; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Eliakim-Raz N; Vuong C; MacGowan A; Addy I; Pujol M;
Antimicrob Resist Infect Control; 2018; 7():111. PubMed ID: 30220999
[TBL] [Abstract][Full Text] [Related]
42. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.
Parchem NL; Bauer KA; Cook CH; Mangino JE; Jones CD; Porter K; Murphy CV
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1433-9. PubMed ID: 27230510
[TBL] [Abstract][Full Text] [Related]
43. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis.
Righi E; Peri AM; Harris PN; Wailan AM; Liborio M; Lane SW; Paterson DL
J Antimicrob Chemother; 2017 Mar; 72(3):668-677. PubMed ID: 27999023
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
[TBL] [Abstract][Full Text] [Related]
45. Colistin: new lessons on an old antibiotic.
Yahav D; Farbman L; Leibovici L; Paul M
Clin Microbiol Infect; 2012 Jan; 18(1):18-29. PubMed ID: 22168320
[TBL] [Abstract][Full Text] [Related]
46. A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
Chest; 2019 Jun; 155(6):1119-1130. PubMed ID: 30685333
[TBL] [Abstract][Full Text] [Related]
47. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
Werarak P; Kiratisin P; Thamlikitkul V
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
[TBL] [Abstract][Full Text] [Related]
48. Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem.
Perdigão Neto LV; Oliveira MS; Martins RCR; Marchi AP; Gaudereto JJ; da Costa LATJ; de Lima LFA; Takeda CFV; Costa SF; Levin AS
J Antimicrob Chemother; 2019 Jan; 74(1):177-181. PubMed ID: 30376073
[TBL] [Abstract][Full Text] [Related]
49. Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population.
Goverman J; Weber JM; Keaney TJ; Sheridan RL
J Burn Care Res; 2007; 28(3):421-6. PubMed ID: 17438490
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness and safety of colistin: prospective comparative cohort study.
Paul M; Bishara J; Levcovich A; Chowers M; Goldberg E; Singer P; Lev S; Leon P; Raskin M; Yahav D; Leibovici L
J Antimicrob Chemother; 2010 May; 65(5):1019-27. PubMed ID: 20299494
[TBL] [Abstract][Full Text] [Related]
51. The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.
Benattar YD; Omar M; Zusman O; Yahav D; Zak-Doron Y; Altunin S; Elbaz M; Daitch V; Granot M; Leibovici L; Paul M
Clin Infect Dis; 2016 Dec; 63(12):1605-1612. PubMed ID: 27794023
[TBL] [Abstract][Full Text] [Related]
52. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014.
Yang P; Chen Y; Jiang S; Shen P; Lu X; Xiao Y
Antimicrob Resist Infect Control; 2018; 7():137. PubMed ID: 30479750
[TBL] [Abstract][Full Text] [Related]
53. Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections.
Aydın M; Ergönül Ö; Azap A; Bilgin H; Aydın G; Çavuş SA; Demiroğlu YZ; Alışkan HE; Memikoğlu O; Menekşe Ş; Kaya Ş; Demir NA; Karaoğlan I; Başaran S; Hatipoğlu Ç; Erdinç Ş; Yılmaz E; Tümtürk A; Tezer Y; Demirkaya H; Çakar ŞE; Keske Ş; Tekin S; Yardımcı C; Karakoç Ç; Ergen P; Azap Ö; Mülazımoğlu L; Ural O; Can F; Akalın H;
J Hosp Infect; 2018 Mar; 98(3):260-263. PubMed ID: 29248504
[TBL] [Abstract][Full Text] [Related]
54. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
Huang J; Tang YQ; Sun JY
Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
[TBL] [Abstract][Full Text] [Related]
55. Short-course aminoglycosides as adjunctive empirical therapy in patients with Gram-negative bloodstream infection, a cohort study.
Deelen JWT; Rottier WC; Buiting AGM; Dorigo-Zetsma JW; Kluytmans JAJW; van der Linden PD; Thijsen SFT; Vlaminckx BJM; Weersink AJL; Ammerlaan HSM; Bonten MJM; van Werkhoven CH
Clin Microbiol Infect; 2021 Feb; 27(2):269-275. PubMed ID: 32387438
[TBL] [Abstract][Full Text] [Related]
56. Combination therapy vs. monotherapy for Gram-negative bloodstream infection: matching by predicted prognosis.
Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
Int J Antimicrob Agents; 2018 Mar; 51(3):488-492. PubMed ID: 28919195
[TBL] [Abstract][Full Text] [Related]
57. Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock.
Guillamet MCV; Damulira C; Atkinson A; Fraser VJ; Micek S; Kollef MH
Int J Antimicrob Agents; 2023 Oct; 62(4):106913. PubMed ID: 37422096
[TBL] [Abstract][Full Text] [Related]
58. Incidence and outcomes of multidrug-resistant gram-negative bacteria infections in intensive care unit from Nepal- a prospective cohort study.
Siwakoti S; Subedi A; Sharma A; Baral R; Bhattarai NR; Khanal B
Antimicrob Resist Infect Control; 2018; 7():114. PubMed ID: 30275945
[TBL] [Abstract][Full Text] [Related]
59. A Cohort Study of the Impact of Carbapenem-Resistant
Sabino S; Soares S; Ramos F; Moretti M; Zavascki AP; Rigatto MH
mSphere; 2019 Apr; 4(2):. PubMed ID: 30971443
[TBL] [Abstract][Full Text] [Related]
60. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
